natgillin/translations-raw huggingface dataset:
is substituted or unsubstituted cycloalkyl; and is H, or a substituted or unsubstituted C1-8 alkyl; 
je supstituiran ili nesupstituiran cikloalkil; i R3 je H ili supstituirano ili nesupstituirani C1-8 alkil;
Patent Literature 4: European Patent No. 125023 
Datum podnošenja europske prijave patenta:
A window or door as claimed in claim 1, wherein said wiring means extend across said openable door element and said frame for electric connection of said motor to the mains. 
Prozor ili vrata prema zahtjevu 3 ili 4, gdje se vodiči pružaju duž elementa vrata koja se mogu otvoriti i okvira radi električne veze motora s glavnim izvorom.
wherein is a member selected from the group consisting of: 
R! član odabran iz grupe koja se sastoji od: cili)
obtaining (S547) the PLP data from the signal frame; and 
analiziranja okvira signala od primljenog signala ln nn na na nn nn
The antibody drug conjugate for use according to any one of claims 1-22, wherein the anti-DLL3 antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 212 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 213. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 5, naznačen time, da protutijelo anti-DLL3 obuhvaća varijabilno područje slabog lanca koje obuhvaća aminokiselinsku sekvencu prema SEQ ID NO:212 1 varijabilno područje jakog lanca koje obuhvaća aminokiselinsku sekvencu prema SEQ ID NO:213.
The method of claim 1, wherein adjusting the gain parameter includes enabling gain attenuation to reduce a gain value corresponding to a frame of the audio signal. 
Postupak prema zahtjevu 1, gdje podešavanje parametra pojačanja podrazumijeva omogućavanje slabljenja pojačanja kako bi se umanjila vrijednost pojačanja koja odgovara sklopu audio signala.
The rim block cage according to one of the preceding claims, characterized in that the flushing water distribution element (8) is provided jointly for all containers (3a, 3b, 3c, 3d). 
WC košarica prema jednom od prethodnih zahtjeva, naznačena time da je element za distribuciju vode za ispiranje (8) zajednički za sve spremnike (3a, 3b, 3c, 3d).
In one aspect of the present invention, the GPR119 agonist is a compound of Formula (V). 
Postupak u skladu sa zahtjevom 12 ili zahtjevom 13, naznačen time, da GPR119 agonist je agonist humanog
In this alternative process, 10-DAB, Formula 34, is first protected at both the C-7 and C-10 positions to form C7,C10 di-CBZ 10-deacetylbaccatin III, Formula 35, according to the following reaction: 
U ovom alternativnom postupku, 10-DAB, formula 34, je najprije zaštićen na oba položaja C-7 i C-10 da bi se formirao C7, C10 di-CBZ 10-deacetilbakatin III, formula 35, prema sljedećoj reakciji:
The pharmaceutical composition according to claim 15, wherein the other anti-HCV agent is an immunomodulatory agent selected from a-, B-, δ- Y-, t-and w-interferon and pegylated forms thereof. 
Farmaceutski sastav prema zahtjevu 15, naznačen time, da je sljedeće anti-HCV-sredstvo jedno imunomodulacijsko sredstvo odabrano od a-, B-, δ-Y-, t- i w-interferona te od njihovih pegiliranih oblika.
The compound of claim 19, wherein said compound is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2.4]triazole, or a tautomer, pharmaceutically acceptable salt, solvate, or clathrate thereof. 
Spoj prema zahtjevu 19, pri čemu je navedeni spoj 3-(2,4-dihidroksi-5-izopropil-fenil)-4-(1-metil-indol-5-il)-5hidroksi-[1,2,4]-triazol ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat.
The human T cell of claim 1, wherein the 4-1BB costimulatory signaling region comprises the amino acid sequence of SEQ ID NO:23. 
(i) - kostimulatorno signalno područje 4-1 BB sadrži aminokiselinsku sekvencu naznačenu u SEQ ID NO: 23;
taking, as a sample portion, a first percentage of the tissue engineered product containing cells and a proportional second percentage of the cell culture conditioned medium; 
(a) pripreme dijela uzorka produkta preinačenog-tkiva koji sadržava stanice i proporcionalnu količinu kondicioniranog medija stanične kulture;
Culture media usually contained up to about 10% of animal serum, such as fetal bovine serum (FBS), also called fetal calf serum (FCS). 
Medij za uzgoj uobičajeno je sadržavao do 10 % animalnog seruma, poput fetalnog goveđeg seruma (FBS) zvanog još i fetalni teleći serum (FCS).
A pallet container according to claim 1, wherein in the collapsed condition the opposed side frames are positioned laying adjacent the base of the pallet container. 
Paletni spremnik prema zahtjevu 1, naznačen time da su u sklopljenom stanju nasuprotni bočni okviri postavljeni da leže neposredno uz osnovicu paletnog spremnika.
wherein the A3 domain comprises a permissive loop-1 (A3-1) region and a permissive loop-2 (A3-2) region; 
pri čemu A3 domena sadrži regiju permisivne petlje-1 (A3-1) i regiju permisivne petlje-2 (A3-2) u koje se može umetnuti heterologni dio bez uklanjanja prokoagulantske aktivnosti rekombinantnog proteina;
The invention also provides the use of (a) IL-2 microaggregates of the invention and (b) a second pharmaceutical agent, in the manufacture of a combination medicament. 
Izum također daje uporabu (a) IL-2 mikroagregata iz izuma i (b) drugog farmaceutskog agensa u proizvodnji kombinacijskog pripravka lijeka.
separating the trans-(-)-A9-tetrahydrocannabinol and/or the trans-(+)-A9-tetrahydrocannabinol from the alcoholic-caustic phase; and 
(b) separaciju trans-(-)-A*-tetrahidrokanabinola i/ili trans-(+)-A*-tetrahidrokanabinola od alkoholno-kaustične faze; i
reaction (O-reac) is a reaction of compound of formula (XXIII), with a reagent (O-reag); 
Kod reakcije (O-reak.) radi se o reakciji spoja formule (XXII) sa reagensom (O-reag.);
The aqueous pharmaceutical suspension according to claim 7, wherein the sorbic acid or potassium sorbate is, by weight/volume (g/100 mL), about 0.10% to about 0.22%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što sorbinska kiselina ili kalijev sorbat iznosi, težinski/volumno (g/100 ml), otprilike 0,10 % do otprilike 0,22 %.
Thus a cylindrical boss is divided by four angularly equi-spaced, elongate flutes 29 to define four quarter-cylindrical lands 31 . 
To znači da je cilindrična glava podijeljena na četiri izdužena žlijeba 29 na međusobno podjednakom razmaku tako da definira četiri, od po jedne četvrtine, cilindrična polja 31.
A screen comprising at least two, or even at least three, or even at least four, or even at least five, screen panels as claimed in claim 1 and interconnected in pairs. 
Zaslon koji sadrži najmanje dvije, ili čak najmanje tri, ili čak najmanje četiri, ili čak najmanje pet, zaslonskih ploča prema bilo kojem od prethodnih patentnih zahtjeva i koje su međusobno povezane u parovima.
In an embodiment of the present R4 is selected from the group consisting of hydrogen and methyl, preferably, R4 is hydrogen. In an embodiment of the present invention a is 1. 
R* je odabran iz skupine koju sačinjavaju vodik i niži alkil; a je cijeli broj od 1 do 2; je odabran iz skupine koju sačinjavaju 5 Z
The isolated antibody of claim 8, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 52 and the light chain comprises the amino acid sequence of SEQ ID NO: 53. 
Izolirano protutijelo u skladu s patentnim zahtjevom 8, naznačeno time, da teški lanac sadrži aminokiselinski slijed IDENTIFIKACIJSKOG BR.
Ar1 is neither a substituted or unsubstituted pyrazolo[1,5-a]pyridin-2yl nor a substituted or unsubstituted pyrazolo[1,5-a]pyrimidin-2yl moiety; and the compound of formula I is none of: 
Ar1nije ni supstituirani ili nesupstituirani pirazolo[1,5-a]piridin-2-il ni supstituirani ili nesupstituirani pirazolo[1,5-a]pirimidin-2il dio; i spoj formule i nije ni jedno od:
the targeted genetic modification comprises simultaneous deletion of an endogenous nucleic acid sequence at the genomic locus of interest and insertion of the insert nucleic acid at the genomic locus of interest, optionally wherein the deleted endogenous nucleic acid sequence is from 30 kb to about 110 kb, and the insert nucleic acid is from about 40 kb to about 140 kb; 
ciljna genetska modifikacija sadrži istovremenu deleciju sekvence endogene nukleinske kiseline na genomskom lokusu od interesa i inserciju inserta nukleinske kiseline na genomskom lokusu od interesa, izborno naznačeno time da deletirana sekvenca endogene nukleinske kiseline je od 30 kb do oko 110 kb, i insert nukleinske kiseline je od oko 40 kb do oko 140 kb;
A flask equipped with a drying tube under N2 atmosphere was charged with anhydrous DMF (250 mL). 
Tikvica opremljena cijevčicom za sušenje uz N, atmosferu je napunjena s anhidridnim DMF (250 mL).
a nucleotide reverse transcriptase inhibitor; wherein TMC278 and the nucleotide reverse transcriptase inhibitor are therapeutically effective HIV inhibitors at a dose that can be administered once daily. 
inhibitor nukleotidne reverzne transkriptaze; pri čemu su TMC278 i inhibitor nukleotidne reverzne transkriptaze terapeutski učinkoviti inhibitori HIV-a u dozi koja se može davati jednom dnevno.
Method of producing fuel for energetics according to claim 8 characterized by that the liquid heat carrier (8) used for heating of the pressure vessels (1) is a liquid based on oil, which is heated up to a temperature of 120 to 300 ° C. and the temperature of the liquid is held in this temperature range for the period of continuous drawing off of the generated gases from the pressure vessels (1). 
HR P2010975 TI Način za proizvodnju goriva za energetiku na temelju zahtjeva 8, naznačen time što se kao medij za prijenos topline (8) za zagrivanje tlačnih posuda (1) koristi tekućina na bazi ulja, koja se zagrijeva na temperaturu 120 až 300" C i ova temperatura se održava tijekom kontinualnog odvođenja nastalih plinova iz tlačnih posuda (1) i u ovom temperaturnom opsegu se njezina temperatura održava.
For example, this form remains, dry at 80% relative humidity and thermodynamically stable at temperatures below 200° C. 
Polimorfni oblik spoja (IX), koji ostaje suh kod 80%-tne relativne vlažnosti i termodinamički je stabilan na temperaturama ispod 200 "C:
In a second aspect the invention provides a method of forming a compound of formula (IV): wherein R1 in each occurrence is independently selected from H, halogen, amino, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl; R2 in each occurrence is independently selected from H, halogen, amino, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl; and R4 is C1-5 alkyl; 
R' je u svakom slučaju neovisno odabran od H, halogena, amino, C,.5 alkila, C25 alkenila 1 C2 5 alkinila; R? jeu svakom slučaju neovisno odabran od H, halogena, amino, C1.5 alkila, C2_5 alkenila 1 C2.5 alkinila; postupak sadrži korak reakcije spoja formule (III) sa spojem 2-etilhekanoatna sol: m
An infant and/or toddler nutrition comprising a non-digestible oligosaccharide A and/or B, said non-digestible oligosaccharide having a degree of polymerisation of 2 to 200 and non-viable Bifidobacterium breve in an amount equivalent to 103 to 1013cfu B. breve per g dry weight of the infant and/or toddler nutrition, and comprising an amount of viable Bifidobacterium breve of less than 103 cfu B. breve per g dry weight of the infant and/or toddler nutrition. 
HR P20190180 T1 PATENTNI ZAHTJEVI nos Hrana za dojenčad i/ili dijete koja sadrži neprobavljivi oligosaharid A i/ili B, navedeni neprobavljivi oligosaharid ima stupanj polimerizacije od 2 do 200 i nevijabilnu Bifidobacterium breve u količini koja je ekvivalenta 103 do 1013 cfu B. breve po g mase suhe tvari hrane za dojenčad i/ili dijete, te sadrži manje od 103 cfu vijabilne Bifidobacterium breve po g mase suhe tvari hrane za dojenčad i/ili dijete.
treating XI with an oxidizing agent to afford I; 
(D obrada XI s oksidirajućim sredstvom, kako bi se dobio I;
FIG. 3: Schematic representation of the elimination of the first and the third selection marker from the genome of the immortalized cell obtained by the process of the invention. 
Postupak prema bilo kojem od patentnih zahtjeva 21 do 23, naznačen time da rečeni postupak nadalje obuhvaća korak koji se sastoji od isključivanja prvog selekcijskog biljega iz genoma rečena ptičje stanice.
reagent (M-reag) is selected from the group consisting of p-toluenesulfonylmethyl isocyanide, trifluoromethanesulfonylmethyl isocyanide, methanesulfonylmethyl isocyanide, benzenesulfonylmethyl isocyanide, 4-acetamidobenzenesulfonylmethyl isocyanide and mixtures thereof; 
reagens (M-reag.) će biti odabran iz skupine koja se sastoji iz p-toluolsulfonilmetilizocijanida, trifluormetansulfonilmetilizocijanida, metansulfonilmetil-izocijanida; benzolsulfonilmetilizocijanida; -acetamidobenzolsulfonilmetilizocijanida i njihovih mješavina;
In accordance with embodiments of the present invention, glucose isomerase is further mentioned for use in medicine, for example as a pharmaceutical composition. 
Glukoza izomeraze za uporabu u skladu s bilo kojim zahtjevom 1 do 7, naznačena time, što glukoza izomeraze je sadržana u farmaceutskom sastavu.
According to yet another embodiment of the invention, the locking means comprises 
Aplikator za umetanje prema zahtjevu 1 ili 2, naznačen time što sredstvo za zaključavanje obuhvaća
Device according to claim 5, characterized in that the axis of rotation of the mobile element passes through the centre line (31). 
Uređaj sukladno zahtjevu 5, naznačen time, što os rotacije mobilnog elementa prolazi kroz središnju liniju (31).
Preferably, said first binding domain specific for CD3 is located C-terminally to the second binding domain. 
(b) drugu vežuću domenu koja se specifično veže na ljudski CEA, gdje navedena druga vežuća domena specifična za ljudski CEA sadrži
q is an integer ranging from 0 to 6; and r is an integer ranging from 0 to 5. 
q je cijeli broj unutar intervala od 0 do 6; a r je cijeli broj unutar intervala od 0 do 5.
Frame according to claim 11, wherein the bearing portion (10) in which said seat (16) is obtained has a longitudinal size that is greater than the longitudinal size of the other bearing portion (10). 
Okvir u skladu sa patentnim zahtjevom 11, gdje noseći dio (10) u kome navedeno sjedište (16) je dobiveno ima uzdužnu veličinu koja je veća od uzdužne veličine drugog nosećeg dijela (10).
The gypsum wall board of any one of the preceding claims wherein the organic-inorganic composite further comprises a cellulose ether selected from the group consisting of hydroxypropylmethyl cellulose, methyl cellulose, hydroxyethylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, cationic cellulose, carboxymethyl cellulose and combinations thereof. 
Zidna gips ploča prema bilo kojem od prethodnih zahtjeva, naznačena time, da organsko-anorganski kompozit nadalje obuhvaća celulozni eter odabran iz skupine koju čine hidroksipropilmetil-celuloza, metil-celuloza, hidroksietilmetil-celuloza, hidroksietil-celuloza, hidroksipropil-celuloza, kationska celuloza, karboksimetil-celuloza i njihove kombinacije.
An isolated IL-1B specific antigen binding protein according to claim 1, consisting of: 
Komplet dviju izoliranih nukleinskih kiselina koje zajedno kodiraju izolirani protein koji veže antigen prema patentnom zahtjevu 1, naznačen time što:
a shank (22) or pilot device protruding from the flange and having an end (26) provided with a threaded hole (23), 
Držač (22) ili pilot uređaj koji viri 12 prirubnice i ima kraj (26) opskrbljen otvorom s navojem (23),
In some embodiments of the third, fourth or fifth aspects of the invention, the eye disease may be selected from the group comprising diabetic retinopathy, corneal edema, anterior and posterior uveitis, pterygium, corneal diseases, dry eye, conjunctivitis, allergy- and laser-induced exudation, macular degeneration, macular edema, age-related macular degeneration and ocular von Hippel-Lindau disease. 
Me ili njegova farmaceutski prihvatljiva sol; za uporabu u liječenju bolesti oka povezane s upalom i/ili vaskularnom proliferacijom u subjektu; naznačen time što je bolest oka odabrana iz skupine koja sadrži dijabetsku retinopatiju, edem rožnice, prednji i stražnji uveitis, pterigij, bolesti rožnice, suho oko, konjunktivitis, izlučivanje uzrokovano alergijom i laserom, makularnu degeneraciju nepovezanu s dobi, makularni edem, makularnu degeneraciju povezanu s dobi i očnu von Hippel-Lindau bolest.
The method of claim 10 wherein the other anti-epileptic is levetiracetam, gabapentin, topiramate, or carbamazepine. 
Spoj, ili sol, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što je drugi antiepileptik levetiracetam, gabapentin, topiramat ili karbamazepin.
A suspension according to claim 1, characterized in that riluzole or said pharmaceutically acceptable salt thereof is in amounts lower than 10% w/v, preferably lower than 5% w/v, more preferably from 0.3% to 4.0% w/v. 
Suspenzija u skladu s patentnim zahtjevom 1, naznačena time što riluzol ili navedena njegova farmaceutski prihvatljiva sol dolaze u količinama ispod 10% tež./vol., po mogućnosti ispod 5% tež./vol., poželjnije od 0,3% do 4,0% tež./vol.
is a monocyclic heteroaryl group, wherein said heteroaryl group has one substituent (R1), and further wherein said heteroaryl group is covalently bonded to the remainder of the molecule through a ring carbon atom; 
je monociklička heteroaril-skupina, pri čemu navedena heteroaril-skupina ima jedan supstituent (R1), i nadalje time, da je navedena heteroaril-skupina kovalentno vezana na ostatak molekule preko prstenskog atoma ugljika;
A compound according to claim 1 selected from the group consisting of: and and pharmaceutically acceptable salts thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se bira iz skupine koju čine: i njihove farmaceutski prihvatljive soli.
The process according to claim 6, characterized in that the fatty acid mixture is melted into the feed mixture in a conditioner, preferably in a long term conditioner, and further more preferably in the presence of an emulsifier. 
Krmna smjesa za preživače prema zahtjevu 1, naznačena time što mješavina masnih kiselina ima jodni broj od najviše 4, poželjno najviše 2, poželjnije najviše 1,5 i najpoželjnije ≤ 1.
The pharmaceutically acceptable formulation of any one of clauses (36)-(42) wherein said formulation is suitable for substantially continuous subcutaneous, intraduodenal or intravenous administration. 
Farmaceutski prihvatljiv tekući sastav iz bilo kojeg zahtjeva 1 do 6, formuliran za kontinuiranu subkutanu, transdermalnu, intrađuodenalnu ili intravenoznu primjenu.
Such optional linker groups are discussed further below. 
Takve eventualne vezne grupe diskutirane su detaljnije u nastavku.
A system of claim 1 or claim 2 wherein the first and second phase contact devices (400, 401) are releasably coupled together, the first and second phase contact devices each optionally comprising releasably interconnected plates, the plates comprising a pair of plates which are in opposed face-to-face relationship and which define between their opposed faces a length of the conduit extending in a direction parallel with the pair of plates, and wherein one plate of the pair of plates of the first phase contact device is shared by the second phase contact device to form one plate of the pair of plates of the second phase contact device. 
Sustav sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačen time, da su prvi i drugi fazno kontaktni uređaji (400, 401) otpustivo spojeni, prvi i drugi faznokontaktni uređaji svaki opcijski obuhvaća odstojno međusobno povezane ploče, te ploče obuhvaćaju par ploča koje su suprotnom odnosu licem u lice i koji između njihovih suprotnih lica definiraju dužinu voda koji se pruža u smjeru paralelnom s parom ploča, i pri čemu jedna ploča od tog para ploča prvog faznokontaktnog uređaja je zajednička s drugim faznokontaktnim uređajem da formira jednu ploču od para ploča drugog faznokontaktnog uređaja.
In this connection, see for instance the patent publication EP-A-1 034 729. 
S tim u vezi vidjeti primjerice patent EP-A-1 034 729.
The output 90 u of the amplifier 90 is connected to both an input pin of the unit 50 and to star-connected feedback resistors 74, 75, 76; the series of the first two resistors is connected to the non-inverting pin of amplifier 90, while the third resistor couples the common node of resistors 74, 75 to a resistive divider shunting the second supply voltage of 5.1V. 
Izlaz 90u, pojačala 90 je spojen na ulazni pin jedinice 60 i na otpornike 74,75,76 spojene u zvijezdu; serijski spoj prva dva otpornika je spojena na invertorski pin pojačala 90, dok treći otpornik spaja zajedničku točku otpornika 74, 75 na otporni djelitelj koji premoštava drugi izvor napona 5.1 V.
Process according to claim 22 wherein the chromatographic technique is HPLC, size-exclusion chromatography, adsorption chromatography, ion exchange chromatography, hydrophobic interaction chromatography or affinity chromatography, chromatography on ceramic hydroapatite. 
* standardnim kromatografskim tehnikama, koje se bira između HPLC-a, gel-permeacijske kromatografije, adsorpcijske = kromatografije, = ionsko-izmjenjivačke - kromatografije, -kromatografije s = hidrofobnim međudjelovanjem ili afinitetne kromatografije, kromatografije na keramičkom hidroapatitu;
cyano, a C1-6 alkoxy (particularly, methoxy, isopropoxy, tert-butoxy) optionally having 1 to 3 substituents selected from 
(1i) cijano, (c) Cr alkoksi koji opcijski ima 1 do 3 supstituenta odabrana od sljedećih:
Adhesive composition according to claim 1, wherein the adhesion promoter consists of one or more salts of alkyl ether sulphates, wherein the cation is a cation of organic or inorganic origin and the anion has formula CH3(CH2)mCH2(OCH2CH2)nOSO3- with m varying from 6 to 22, preferably from 8 to 16 and still more preferably is equal to 10 and n varying from 1 to 5, preferably is equal to 1 or 2. 
Adhezivna kompozicija u skladu sa patentnim zahtjevom 1, pri čemu se adhezivni promoter sastoji od jedne ili više soli alkil eter sulfata, pri čemu kation je kation organskog ili neorganskog porekla a anion ima formulu CH3(CH2)mCH2(OCH2CH2)nOSO3- sa m koje varira od 6 do 22, poželjno od 8 do 16 i još poželjnije jednako je 10 a n varira od 1 do 5, poželjno jednako je 1 ili 2.
The use of claim 56, wherein the disease is an autoimmune disease and is transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis, or multiple sclerosis. 
Upotreba u skladu s patentnim zahtjevom 56, naznačena time što navedena bolest je autoimuna bolest, koja je odbacivanje presatka, bolest reakcije primaoca na presadak, reumatoidni artritis, amiotrofna lateralna skleroza ili multipla skleroza.
The compound according to claim 1, wherein the compound is or a pharmaceutically acceptable salt thereof. 
< ili njihovu farmaceutski prihvatljivu sol. Spoj prema zahtjevu 1, naznačen time da spoj je o